


Listing of the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.


Amendments to the Claims

Claim 1 (Currently Amended) A compound of formula I:



I

wherein R⁴ is selected from:



X represents H, halogen, CN or methyl;

R¹ represents H or C₁₋₄alkyl which is optionally substituted with OH or C₁₋₄alkoxy; or R¹ and R² together complete a heterocyclic ring of 3-7 members bearing 0-2 substituents, in addition to R³, selected from halogen, oxo, NO₂, CN, CF₃, C₁₋₆alkyl, C₂₋₆acyl, C₂₋₆alkenyl, C₁₋₆alkoxy, C₁₋₆alkoxycarbonyl and Ar;

when R¹ represents H or optionally substituted C₁₋₄alkyl, R² and R³ independently represent H, C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₃₋₆cycloalkyl, C₁₋₆alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, Ar, heterocyclyl, or heterocyclylC₁₋₆alkyl, wherein the alkyl, cycloalkyl, alkenyl and alkynyl groups optionally bear one substituent selected from halogen, CF₃, NO₂, CN, Ar, ArCH₂O, ArO, OR¹¹, SR¹¹, SO₂R¹², COR¹¹, CO₂R¹¹, CON(R¹¹)₂, OCOR¹², N(R¹¹)₂ and NR¹¹COR¹²; and the heterocyclic groups optionally

~~bear up to 3 substituents independently selected from halogen, NO₂, CN, R¹², Ar, ArCH₂O, ArO, ArOCH₂, -OR¹¹, -SR¹¹, -SO₂R¹², -COR¹¹, -CO₂R¹¹, -CON(R¹¹)₂, -OCOR¹², -N(R¹¹)₂ and -NR¹¹COR¹²;~~

~~or R² and R³ together with the nitrogen to which they are mutually attached complete a mono-~~
~~or bicyclic~~ monocyclic heterocyclic ring system of 5-10 ring atoms selected from C, N, O and S, said
ring system optionally having an additional benzene or heteroaryl ring fused thereto, said heterocyclic
system and optional fused ring bearing 0-3 substituents independently selected from halogen, oxo,
NO₂, CN, R¹², Ar, ArCH₂O, ArO, ArOCH₂, -OR¹¹, -SR¹¹, -SO₂R¹², -COR¹¹, -CO₂R¹¹, -CON(R¹¹)₂,
-OCOR¹², -N(R¹¹)₂ and -NR¹¹COR¹²;

and when R¹ completes a ring with R², R³ represents H, C₁₋₆alkyl, C₂₋₆acyl, C₂₋₆alkenyl or
benzyl;

m is 0 or 1, with the proviso that when m is 1 neither R² nor R³ is H and R³ is not acyl, and that
m is 1 when X and R¹ are both H;

R¹¹ represents H or R¹²;

R¹² represents C₁₋₆alkyl which optionally bears up to 3 halogen substituents or one substituent
selected from CN, OH, C₁₋₄alkoxy and C₁₋₄alkoxycarbonyl;

~~Y represents halogen, CN or methyl;~~


~~Z represents -OR¹¹ or -N(R⁵)R⁶;~~

~~R⁵ and R⁶ have the same definition as R² and R³ in the embodiment in which R¹ is H or
optionally substituted C₁₋₄alkyl;~~

R¹⁴ represents H or C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₆cycloalkylC₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,
phenyl or benzyl, any of which optionally bear up to 3 halogen substituents or one substituent selected
from CN, NO₂, OH, C₁₋₄alkoxy, CO₂H, C₁₋₄alkoxycarbonyl, C₂₋₆acyl, C₂₋₆acyloxy, amino,
C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₂₋₆acylamino, carbamoyl, C₁₋₄alkylcarbamoyl and di(C₁₋₄
alkyl)carbamoyl; and

Ar represents phenyl or heteroaryl either of which optionally bears up to 3 substituents
independently selected from halogen, CF₃, NO₂, CN, OCF₃, C₁₋₆alkyl and C₁₋₆alkoxy;
or a pharmaceutically acceptable salt thereof.

Claim 2 (Original) A compound according to claim 1 of formula II:



II

or a pharmaceutically acceptable salt thereof.

Claims 3-4 (Canceled)

Claim 5 (Original) A compound according to claim 4 wherein R^{14} is 2,2,2-trifluoroethyl, X is F, CN or methyl, and R^1 is H.

Claim 6 (Original) A compound according to claim 4 wherein m is 1 and X and R^1 are both H.

Claims 7-9 (Canceled)

Claim 10 (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutical carrier.

Claim 11-12 (Cancelled)

Claim 13 (Previously Presented) A method of treatment of a subject suffering from or prone to Alzheimer's disease comprising administering to that subject an effective amount of a compound according to claim 1.